Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02999230 · ClinicalTrials.gov registry record · NA
Probiotics That Moderate pH and Antagonize Pathogens to Promote Oral Health
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 170
- Enrollment target
NCT02999230: Completed NA study, sponsored by University of Florida.
NCT02999230 is a NA study that has completed, run by University of Florida. The registered enrollment target is 170 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02999230, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
Study Summary
This study will examine the mechanisms of action of probiotics and synbiotics for control of oral diseases, with a particular focus on exploring new strategies for caries prevention and treatment.
Primary Outcome
Saliva and dental plaque will be collected during the baseline and week 2 study visits. The amount of ammonia and/or citrulline produced via the ADS by oral bacteria present in the collected oral samples will be measured and compared using standardized protocols.
Interventions
- OTHER Caries Free 1.5% Arginine
- OTHER Caries Free Placebo Sodium Fluoride
- OTHER Caries Active 1.5% Arginine
- OTHER Caries Active- Placebo Sodium Fluoride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2020-06-25 |
| Phase | NA |
What the finished NCT02999230 record still lists
NCT02999230 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 4 interventions - of which Caries Free 1.5% Arginine is the first listed.
NCT02999230 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02999230 about?
NCT02999230 is a clinical study titled "Probiotics That Moderate pH and Antagonize Pathogens to Promote Oral Health". This study will examine the mechanisms of action of probiotics and synbiotics for control of oral diseases, with a particular focus on exploring new strategies for caries prevention and treatment.
What is the current status of trial NCT02999230?
This trial is currently completed. It is a NA study. The enrollment target is 170 participants. The study started on 2017-02-22. Estimated completion is 2020-06-25.
What interventions are being tested in trial NCT02999230?
The interventions under investigation include: Caries Free 1.5% Arginine (OTHER), Caries Free Placebo Sodium Fluoride (OTHER), Caries Active 1.5% Arginine (OTHER), Caries Active- Placebo Sodium Fluoride (OTHER).
Who is sponsoring clinical trial NCT02999230?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02999230's enrollment target sits among peer trials
170 614th of 2000 higher than 1,382 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI